Reuters logo
BRIEF-Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN
November 7, 2017 / 12:42 AM / 14 days ago

BRIEF-Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN

Nov 6 (Reuters) - Cellectis SA

* FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN

* Says ‍working with investigators and clinical sites to obtain IRB‘S approval on revised protocols and resume patient enrollment​

* Cellectis SA says ‍agreed with FDA to decrease of cohort dose level to 6.25x10(4) UCART123 cells/ in Phase 1 UCART123 protocols​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below